Summary of Voyager Therapeutics FY Conference Call Company Overview - **Company**: Voyager Therapeutics (NasdaqGS: VYGR) - **Industry**: Biotechnology, specifically focusing on gene therapy and treatments for neurodegenerative diseases, particularly Alzheimer's disease Key Points 1. Strategic Focus Areas - **Three Pillars of Value**: - **Tau Target**: Focus on tau as a target for Alzheimer's with two programs: VY7523 (anti-tau antibody) and VY-1706 (gene therapy) [2][3] - **Gene Therapy**: Plans to advance two gene therapy assets into clinical trials, one in partnership with Neurocrine and one wholly owned by Voyager [2] - **NeuroShuttle Platform**: Development of a platform to deliver various drugs across the blood-brain barrier [3] 2. Tau as a Target for Alzheimer's - **Importance of Tau**: The spread of tau in the brain correlates more closely with clinical decline in Alzheimer's than amyloid accumulation [6] - **Recent Developments**: Upcoming data from J&J and Biogen on tau-targeting therapies will provide further validation for tau as a target [5][6] - **Mixed Results from Competitors**: UCB's bepranemab showed some effect on tau spread but failed to meet primary clinical endpoints, indicating the complexity of targeting tau [8][9] 3. Clinical Development Insights - **VY7523**: Preliminary safety data shows a favorable profile, with a brain-to-plasma ratio of 0.3% and a half-life supporting monthly dosing [20] - **MAD Study Design**: The multiple ascending dose (MAD) study is designed to assess the effect on tau PET imaging, which is the key biomarker for evaluating the spread of pathological tau [21] - **Future Studies**: Plans to include tau PET imaging data in future studies and emphasize its importance over fluid-based biomarkers [24][25] 4. Gene Therapy Developments - **VY-1706**: Aiming for a 50%-70% reduction in tau mRNA/protein, with a focus on lower doses to enhance safety and reduce costs [31] - **FDA Interactions**: Productive discussions with the FDA regarding trial designs and plans to file an IND in Q2 2026 [33] 5. NeuroShuttle Platform - **Differentiation**: The ALPL shuttle shows longer half-life and no adverse effects on reticulocyte counts compared to transferrin receptor shuttles, making it a promising delivery method for various therapies [46] - **Therapeutic Modalities**: Exploring antibodies, peptides, and oligonucleotides for use with the NeuroShuttle platform [47] 6. Partnerships and Collaborations - **Neurocrine Partnership**: Progress on gene therapy programs, including FA and GBA1, with plans to enter the clinic this year [48] 7. Market Opportunities - **Alzheimer's Disease**: The potential for anti-tau therapies to be used in combination with anti-amyloid treatments, especially for patients who do not respond to the latter [41] - **Broader Applications**: Potential to address other tauopathies beyond Alzheimer's, expanding the market opportunities for Voyager's therapies [42] Additional Insights - **Clinical Predictions**: Anticipation that BIIB080 will show significant effects in clinical measures, which could influence Voyager's approach to VY-1706 [36] - **Patient Population**: Targeting early Alzheimer's patients for clinical trials, aligning with trends in the amyloid treatment landscape [26][27] This summary encapsulates the key discussions and insights from the Voyager Therapeutics FY Conference, highlighting the company's strategic focus, clinical developments, and market opportunities in the biotechnology sector.

Core Viewpoint - Knight Therapeutics Inc. has submitted a marketing authorization application for NIKTIMVO (axatilimab) in Brazil for treating chronic graft-versus-host disease (GVHD) after failure of at least two prior systemic therapies in patients aged 6 years and older [1] Company Developments - Knight Therapeutics expanded its agreement with Incyte for exclusive distribution rights of retifanlimab and axatilimab in Latin America, with Incyte responsible for development and supply, while Knight handles regulatory approvals and distribution [2] - NIKTIMVO received FDA approval in August 2024 for chronic GVHD treatment in patients weighing at least 40 kg after failure of two prior systemic therapies [3] - The CEO of Knight emphasized the importance of new treatment options for chronic GVHD patients, highlighting the company's commitment to improving patient access to effective therapies [4] Industry Context - Chronic GVHD is a significant complication following allogeneic stem cell transplantation, affecting 30%-70% of recipients globally, with approximately 1,400 to 1,800 allogeneic transplants reported annually in Brazil [5] - The cumulative incidence of chronic GVHD after two years is reported to be 29.5% based on recent analyses [5] - NIKTIMVO is a first-in-class CSF-1R-blocking antibody, with ongoing studies for its efficacy in combination therapies for chronic GVHD and other conditions [6][8]

Group 1: Clinical Supply Chain Challenges - The clinical development landscape has evolved, yet many supply chains remain outdated, necessitating strategic adaptations for secure patient access, cost control, and high performance [1] - Modern clinical trial supply chains require technology and analytics to manage complexities such as cold storage for biologics and handling cell and gene therapies [1] Group 2: Importance of Partnerships - Strong relationships with Contract Manufacturing Organisations (CMO) and Contract Research Organizations (CRO) are increasingly vital for trial resilience and success in a changing geopolitical environment [2] - Effective communication strategies and the judicious use of technology can enhance oversight and efficiency in R&D [2] Group 3: Conference Insights - The 27th Annual Clinical Trial Supply (CTS) Europe conference will take place in Barcelona on February 24-25, focusing on clinical supply logistics, operations, technology, and innovation [3] - Keynote speaker Arnaud Dourlens from Sanofi will discuss the need for new models in clinical supply chain development due to increasing uncertainties [4] - Following the keynote, discussions will include Sanofi's interactive response technology (IRT) transformation and its impact on drug supply optimization and operational efficiency [5] - UCB's Maite Montes Vallina will address outsourcing challenges and the importance of effective Importer of Record (IOR) and Exporter of Record (EOR) management [6] - A case study on AI application in pharma supply chains will be presented by Sanofi's Landry Giardina, highlighting insights that drive measurable business outcomes [7]

Core Insights - Syndax Pharmaceuticals is experiencing significant growth driven by its products Revuforj and Niktimvo, with a strong commercial performance expected to continue into 2026 [4][7]. Product Performance - Revuforj has shown a 38% growth in the fourth quarter, attributed to its use in KMT2A-rearranged acute myeloid leukemia (AML) and new momentum in NPM1-mutant AML following recent guideline inclusion and approval [2][3]. - Niktimvo has generated $152 million in net sales within its first 11 months on the market for chronic graft-versus-host disease (GVHD), indicating strong uptake [3][7]. - The company anticipates Revuforj's average treatment duration to increase from 4-6 months to 6-12 months as maintenance adoption rises from 35-40% to an expected 70-80% [6][12]. Market Opportunities - The U.S. market for Niktimvo in the third-line-plus setting is estimated at approximately 6,500 patients, with a frontline opportunity of around 17,000 patients, suggesting a potential approach to $1 billion in sales [5][15]. - Syndax expects to dominate the market share in NPM1-mutant AML, although it is currently too early to quantify [8]. Financial Outlook - The company has guided flat operating expenses at $400 million for 2026 and is fully funded, indicating no immediate need for additional cash [23]. - Syndax's collaboration with Incyte involves a 50/50 profit split, with expectations that 25-30% of Incyte's reported net sales will contribute to Syndax's revenue [16][17]. Clinical Development - Syndax is advancing a Phase II trial in idiopathic pulmonary fibrosis (IPF) with results expected in the second half of 2026, and a Phase II trial combining Niktimvo with Jakafi is anticipated to read out in early 2027 [18][20]. - The company is also exploring myelofibrosis treatment options, with preclinical work showing promising results [13][14].

Summary of Syndax Pharmaceuticals Conference Call Company Overview - **Company**: Syndax Pharmaceuticals (NasdaqGS:SNDX) - **Date**: February 12, 2026 - **Key Speakers**: Michael Metzger (CEO), Nick Botwood (CMO, Head of R&D), Keith Goldan (CFO) Core Points and Arguments Financial Performance - **Revuforj**: Achieved $125 million in annual net sales, with a quarter-over-quarter growth of 38% in Q4 2025, indicating strong market performance and expansion in its labeled indications [2][4] - **Niktimvo**: Generated $152 million in sales within the first 11 months of launch for chronic GVHD, also showing significant quarter-over-quarter growth [2] Product Development and Market Strategy - **Revuforj**: - Focused on KMT2A and NPM1 indications, with new NCCN guidelines and approvals driving growth [4][5] - Anticipated to capture a dominant market share in NPM1, similar to its established position in KMT2A [9] - Current maintenance therapy uptake for KMT2A is 35%-40%, with expectations to grow to 70%-80% over time [10][13] - **Niktimvo**: - Currently approved for later-line chronic GVHD, with a potential market of approximately 6,500 patients in the U.S. for third-line treatment, and an estimated peak opportunity approaching $1 billion [23][24] - Collaboration with Incyte involves a 50/50 profit split, with expectations for long-term growth in revenue share [24][26] Research and Development - **IPF Phase II Trial**: - Expected to read out in the second half of 2026, with a well-designed study focusing on forced vital capacity as the primary endpoint [30][34] - Strong preclinical data supports the role of CSF1R inhibition in IPF, with significant improvements noted in related conditions [32][40] - **Future Opportunities**: - Plans to explore the role of revumenib in myeloproliferative neoplasms (MPN), with promising preclinical results [20][21][22] Path to Profitability - Syndax aims for profitability potentially by 2027, supported by strong revenue from both Revuforj and Niktimvo, while maintaining flat operating expenses at $400 million [46] Additional Important Insights - The company is fully funded and does not require additional cash, positioning it well for future growth [46] - The collaboration with Incyte extends to future trials, including potential IPF studies, with shared costs and responsibilities [45] This summary encapsulates the key points discussed during the conference call, highlighting the financial performance, product development strategies, research initiatives, and the company's path to profitability.

Summary of Avalo Therapeutics Conference Call Company Overview - **Company**: Avalo Therapeutics (NasdaqCM:AVTX) - **Event**: 2026 Conference on February 11, 2026 - **Focus**: Discussion on the upcoming phase 2b data from the LOTUS trial for AVTX-009, a monoclonal antibody targeting IL-1 beta Key Points Industry and Product Insights - **Product**: AVTX-009, a high-affinity anti-IL-1 beta monoclonal antibody - **Trial**: LOTUS trial, over 250 patients, placebo-controlled, focusing on moderate to severe hidradenitis suppurativa (HS) [2][36] - **Expected Data Release**: Phase 2b data anticipated in Q2 2026 [2][60] Mechanism of Action - **IL-1 Beta Role**: Principal driver of inflammation in HS, with higher concentrations than other inflammatory markers [6][14] - **Comparison with Other Drugs**: IL-1 beta is considered more effective than IL-1 alpha in treating HS, as evidenced by the failure of anti-IL-1 alpha drugs like bermekimab [13][14] Trial Design and Execution - **Trial Structure**: Three-arm study comparing two dosing regimens of AVTX-009 against placebo [34][35] - **Patient Population**: Over 250 patients enrolled, including a significant number of biologically experienced patients [37][42] - **Placebo Response**: Historical placebo response rates in HS trials range from 13% to 18% [35] Safety and Efficacy Considerations - **Safety Profile**: Expected increase in bacterial infections and potential for neutropenia, but generally manageable [47] - **Efficacy Expectations**: Aiming for a response rate of 20% or higher beyond placebo, with a potential "home run" at 25% [49][50] Future Directions - **Next Steps**: Plans for two pivotal phase III trials following the LOTUS study data [52] - **Potential Indications**: Interest in expanding into dermatology, rheumatology, and gastrointestinal diseases due to the potency of AVTX-009 [53] Financial Position - **Cash Reserves**: $100 million reported at the end of the previous year, with a burn rate of $50 million [68] Additional Considerations - **Quality of Life Metrics**: Focus on pain relief and quality of life improvements as key endpoints in the trial [54][55] - **Data Release Timeline**: Complete data set expected to include a 6-week safety follow-up, with final patient visits concluding in March 2026 [62][64] This summary encapsulates the critical insights from the Avalo Therapeutics conference call, highlighting the company's strategic focus, product development, and market positioning within the biotech industry.

February 6, 2026 Q4 AND FULL YEAR 2025 FINANCIAL RESULTS AND BUSINESS UPDATE FORWARD-LOOKING STATEMENTS This presentation and discussions during this conference call contain forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; ...

UCB Conference Call Summary Company Overview - **Company**: UCB - **Industry**: Pharmaceuticals, specifically focusing on immunology and neurology - **CEO**: Jean-Christophe Tellier Key Points and Arguments Company Strength and Growth Prospects - UCB is positioned for a decade of growth, supported by strong performance over the past years [2][3] - The company has a nearly century-long history, with a focus on innovation and sustainability [3] - Two main pillars of growth are identified: immunology and neurology, with five growth drivers highlighted [3][4] Product Portfolio and Pipeline - **Bimzelx**: Key product with five indications launched, expected to maintain exclusivity until 2037 [4][5] - Other products include treatments for generalized myasthenia gravis, Dravet syndrome, Lennox-Gastaut syndrome, and fragility fractures [4][15] - **KGV**: Recently approved treatment for TK2d deficiency, an ultra-rare disease in children [11] - **Galbokimic**: A multispecific antibody targeting multiple interleukins, aimed at treating autoimmune diseases [12] - **Bepranemab**: An anti-Tau treatment for Alzheimer's disease, showing potential clinical improvements [13][39] Financial Performance and Investment Strategy - UCB has committed to investing more than peers in R&D, with a $5 billion investment in a new manufacturing facility in the U.S. [6][7] - Projected growth includes a 24% increase in revenue and a 700 basis point improvement in EBITDA by 2025 [9] - The company maintains a strong balance sheet, allowing for strategic flexibility in investments [7][49] Market Dynamics and Competitive Position - UCB aims to balance patient access with pricing strategies, avoiding excessive rebates that could stimulate competition [18][21] - The company has achieved significant coverage, with 36 million additional lives covered in 2026, representing a 25% increase [15][19] - UCB is focused on expanding into new markets, such as hidradenitis suppurativa (HS), which has a significant unmet need [22][23] Future Outlook and Strategic Focus - UCB plans to leverage its strong pipeline and innovative capabilities to address unmet medical needs in various therapeutic areas [17][46] - The company emphasizes the importance of understanding human biology and integrating new scientific advancements into its research [46][47] - Future capital allocation will focus on early-stage research and potential acquisitions to enhance growth drivers [47][48] Additional Insights - The company is exploring partnerships to mitigate risks associated with high-risk assets like bepranemab [40] - UCB is optimistic about the potential of dapirolizumab pegol in lupus, anticipating a second phase 3 trial to confirm safety and efficacy [42][44] Conclusion UCB is strategically positioned for significant growth in the pharmaceutical industry, with a robust pipeline and a commitment to innovation. The company is focused on addressing unmet medical needs while maintaining a strong financial position to support future investments and growth initiatives.

Turning Strategy into Results Jean-Christophe Tellier, CEO 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026 Disclaimer & Safe Harbor This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All sta ...

© 2 0 2 6 O R U K A T H E R A P E U T I C S Disclaimers The information contained in this presentation has been prepared by Oruka Therapeutics, Inc. (the "Company") and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data as well as third party information from other sources; (b) does no ...